Am. Richter et al., ACTIVATION OF BENZOPORPHYRIN DERIVATIVE IN THE CIRCULATION OF MICE WITHOUT SKIN PHOTOSENSITIVITY, Photochemistry and photobiology, 59(3), 1994, pp. 350-355
In vitro experiments with benzoporphyrin derivative monoacid ring A (B
PD) confirmed earlier studies that it was taken up rapidly (within 30
min) to maximum concentrations by all cells tested. It was also confir
med that rapidly dividing tumor cell lines and mitogen-activated murin
e T lymphocytes took up significantly more (5-10-fold) BPD than did no
rmal splenic lymphocytes. Further experiments were undertaken to deter
mine whether BPD could be activated by whole-body irradiation with red
light in the blood of animals, shortly after intravenous (i.v.) admin
istration, in the absence of skin photosensitivity. It was found that
shaved and depilated mice injected i.v. 60 min earlier with BPD at bet
ween 0.5 and 1.0 mg/kg could tolerate 160 J/cm(2) of broad-band red li
ght (560-900 nm) delivered, at a relatively low rate, over a 90 min ti
me interval without developing skin photosensitivity or general photot
oxicity. During the treatment time, plasma levels of BPD were between
0.7 and 1.0 mu g/mL. The light treatment resulted in between 70 and 80
% photoinactivation of circulating BPD. When L1210 tumor cells were pr
eincubated with BPD and injected i.v. into mice immediately before tot
al-body light treatment (160 J/cm(2) of 590-900 nm light delivered ove
r 90 min), significant reductions in circulating clonogenic tumor cell
s were observed in blood samples taken immediately following treatment
. This indicated that sufficient light was being delivered to BPD in t
he blood flowing in the peripheral vasculature to effect cytotoxicity
to cells containing the photosensitizer without causing either vascula
r or skin photosensitivity. Thus, activation of this photosensitizer i
n the circulation can be achieved by transdermal light exposure withou
t causing skin photosensitivity provided that light exposure is perfor
med at a time when the first phase of plasma clearance is complete and
when the drug has not yet accumulated in skin.